Journal of Cystic Fibrosis

Journal

Publication Venue For

  • Exploring provider attitudes and perspectives related to men's health in cystic fibrosis.  21:652-656. 2022
  • Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies–A qualitative study.  21:657-661. 2022
  • Pregnancy in cystic fibrosis: Review of the literature and expert recommendations.  21:387-395. 2022
  • Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study 2022
  • ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction 2022
  • Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.  21:143-145. 2022
  • Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D 2022
  • Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI 2022
  • Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.  21:e8-e10. 2022
  • Sexual and reproductive health experiences and care of adult women with cystic fibrosis 2022
  • Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients 2022
  • Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic.  20:41-46. 2021
  • Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network.  20:57-63. 2021
  • Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors.  20:49-54. 2021
  • 275: A mobile health platform for pediatric cystic fibrosis: Impact on patient-reported outcomes and patient-centered care.  20:s132-s133. 2021
  • 337: Food insecurity in the cystic fibrosis care center network during COVID-19: Prevalence, screening, and interventions.  20:s161. 2021
  • 497: An oral commensal modulates the host immune response to Pseudomonas aeruginosa infection.  20:s235. 2021
  • Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.  20:1026-1034. 2021
  • Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.  20:965-971. 2021
  • Men's health in the modern era of cystic fibrosis.  20:e121-e123. 2021
  • Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.  20:1018-1025. 2021
  • Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.  20:865-875. 2021
  • Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation.  20:e69-e71. 2021
  • Cessation of smoke exposure improves pediatric CF outcomes: Longitudinal analysis of CF Foundation Patient Registry data.  20:618-624. 2021
  • Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.  20:612-617. 2021
  • Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.  20:399-401. 2021
  • Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19.  20:e23-e28. 2021
  • Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.  20:213-219. 2021
  • Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.  20:333-338. 2021
  • PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.  20:205-212. 2021
  • Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).  20:250-256. 2021
  • Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.  20:228-233. 2021
  • Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.  20:25-30. 2021
  • Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.  19:931-933. 2020
  • The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.  19:868-871. 2020
  • In the south, if you give us lemons, we will make you lemonade.  19:842-843. 2020
  • Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis.  19:783-790. 2020
  • Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.  19:742-745. 2020
  • Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).  19:595-601. 2020
  • WS13.3 Tobacco smoke exposure limits the benefit of Symdeko® in paediatric cystic fibrosis patients: Cystic Fibrosis Foundation Patient Registry analysis.  19:s22. 2020
  • Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis.  19:40-48. 2020
  • An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB).  18:838-843. 2019
  • Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis.  18:636-645. 2019
  • Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations.  18:579-580. 2019
  • Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.  18:536-542. 2019
  • P420 Reducing tobacco smoke exposure in paediatric cystic fibrosis: a qualitative examination of caregivers' and clinicians perspectives.  18:s176. 2019
  • Colocolonic intussusception in an adult cystic fibrosis patient.  18:e11-e13. 2019
  • CFTR modulator theratyping: Current status, gaps and future directions.  18:22-34. 2019
  • Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.  18:102-109. 2019
  • Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6–20 years: A pilot study.  17:747-759. 2018
  • WS05.2 Impact of tobacco smoke exposure on pulmonary function in paediatric cystic fibrosis patients.  17:s9. 2018
  • Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis.  17:57-63. 2018
  • Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis.  17:64-70. 2018
  • A multiple reader scoring system for Nasal Potential Difference parameters.  16:573-578. 2017
  • Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.  16:592-599. 2017
  • Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.  16:600-606. 2017
  • Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.  16:371-379. 2017
  • Applying recent advances in the science of CFTR-based therapeutics to improve outcomes in patients with cystic fibrosis 2017
  • Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.  16:24-29. 2017
  • Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.  15:227-233. 2016
  • Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.  15:67-73. 2016
  • Physical activity assessment in cystic fibrosis: A position statement.  14:e25-e32. 2015
  • Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.  14:219-227. 2015
  • Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.  14:228-236. 2015
  • The development and deployment of integrated electronic care records in a regional adult and paediatric cystic fibrosis unit.  13:681-686. 2014
  • Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis.  13:164-171. 2014
  • Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data.  13:139-147. 2014
  • ESCF care guidelines beyond Europe.  13:359-360. 2014
  • Evaluating the predictive ability of sweat chloride.  13:118. 2014
  • Marked repression of CFTR mRNA in the transgenic Cftrtm1kth mouse model.  13:351-352. 2014
  • Spiritual coping predicts 5-year health outcomes in adolescents with cystic fibrosis.  13:593-600. 2014
  • Innate immunity in cystic fibrosis lung disease.  11:363-382. 2012
  • Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation.  11:40-45. 2012
  • Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis.  8:193-197. 2009
  • Bioelectric effects of quinine on polarized airway epithelial cells.  6:351-359. 2007
  • Assessment of CFTR localisation in native airway epithelial cells obtained by nasal brushing.  3:43-48. 2004
  • Gene delivery systems - Gene therapy vectors for cystic fibrosis.  3:203-212. 2004
  • International Standard Serial Number (issn)

  • 1569-1993
  • Electronic International Standard Serial Number (eissn)

  • 1873-5010